Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy

被引：7

作者：

Stelmaszyk, Agnieszka ^{[1
]}

Mikolajczak, Przemyslaw ^{[1
]}

Dworacka, Marzena ^{[1
]}

机构：

[1] Poznan Univ Med Sci, Dept Pharmacol, Uniwersytet Med Karola Marcinkowskiego Poznaiu, Katedra Zaklad Farmakol, Ul Rokietnicka 5A, PL-60806 Poznan, Poland

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2021年 / 907卷

关键词：

Diabetes mellitus; Sirtuin; 1; Metabolic memory; Chronic complications; CELLULAR METABOLIC MEMORY; WHITE ADIPOSE-TISSUE; HIGH GLUCOSE; FATTY LIVER; INDUCTION; PATHWAY; DISEASE; ATHEROSCLEROSIS; ROSIGLITAZONE; EXENATIDE;

D O I：

10.1016/j.ejphar.2021.174289

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

SIRT1 (sirtuin 1, a member of histone deacetylase III family) is responsible for deacetylation of lysine in histones and the conservation of DNA in the state of transcriptionally inactive heterochromatin. SIRT1 is also capable of deacetylation of transcription factors, as well as other regulatory proteins. The SIRT1 activity plays a unique role in the prevention of metabolic memory, reducing many pathways leading to chronic diabetic complications or diseases concomitant with diabetes. Factors modifying expression and/or activity of SIRT1 may be especially helpful for patients with diabetes. This article attempts to sum up the current state of knowledge about agents commonly used in the treatment of type 2 diabetes which might have an impact on the SIRT1 expression and activity. It is the review of several studies regarding drug-induced pleiotropic activity and the way in which their interference with cellular pathways gives us better understanding of this activity, as well as the influence of therapy on the course of the disease.

引用

页数：7